Pancreatic Cancer Research

ResearcherUniversity of CologneActive in the last 2 years

Thomas Schmidt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7166-3675; OpenAlex author ID A5001774072, A5132852820. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 16

  1. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  2. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  3. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  4. Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072049↗
  5. Therapy of Locally Advanced and Oligometastatic Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers15245881↗
  6. [Surgical treatment of pancreatic cancer-What is new?] Co-author DOI 10.1007/s00104-022-01618-7↗
  7. [S3 Guideline "Exocrine Pancreatic Cancer"]. Co-author DOI 10.1007/s00104-022-01689-6↗
  8. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  9. Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer Co-author DOI 10.1101/2021.03.13.435100↗
  10. Cavernous transformation of the portal vein in pancreatic cancer surgery-venous bypass graft first. Co-author DOI 10.1007/s00423-020-01974-0↗
  11. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Last author DOI 10.1038/s41598-020-62416-x↗
  12. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients w… Co-author DOI 10.1080/2162402x.2017.1303584↗
  13. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
  14. Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for… First author DOI 10.1186/1471-2407-14-168↗
  15. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.2651↗
  16. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. First author DOI 10.1186/1471-2407-11-286↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christiane J. Bruns · 5 shared papers, 2022–2024 · strength 0.94
  2. Alexander Ioannis Damanakis · 4 shared papers, 2023–2024 · strength 0.72
  3. Felix Popp · 3 shared papers, 2023–2024 · strength 0.48
  4. Alexander Quaas · 3 shared papers, 2023–2024 · strength 0.48
  5. Su Ir Lyu · 3 shared papers, 2023–2024 · strength 0.48
  6. Karl Knipper · 3 shared papers, 2023–2024 · strength 0.48
  7. Yue Zhao · 3 shared papers, 2023–2024 · strength 0.48
  8. Thilo Hackert · 4 shared papers, 2020–2021 · strength 0.44
  9. Martin A. Schneider · 4 shared papers, 2014–2021 · strength 0.37
  10. Markus Wolfgang Büchler · 5 shared papers, 2011–2021 · strength 0.36
  11. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  12. Utz Settmacher · 2 shared papers, 2023–2024 · strength 0.29
  13. Bettina Rau · 2 shared papers, 2023–2024 · strength 0.29
  14. Markus K. Diener · 3 shared papers, 2015–2021 · strength 0.26
  15. Isabell Wahler · 1 shared paper, 2023 · strength 0.24
  16. Orlin Belyaev · 1 shared paper, 2022 · strength 0.22
  17. Waldemar H. Uhl · 1 shared paper, 2022 · strength 0.22
  18. André L. Mihaljević · 2 shared papers, 2020–2021 · strength 0.22
  19. Oliver Strobel · 2 shared papers, 2020–2021 · strength 0.22
  20. Christoph Springfeld · 3 shared papers, 2015–2021 · strength 0.20
  21. Friedrich Hubertus Schmitz-Winnenthal · 3 shared papers, 2014–2018 · strength 0.14
  22. Philipp Beckhove · 3 shared papers, 2014–2018 · strength 0.14
  23. Niels Halama · 2 shared papers, 2014–2021 · strength 0.14
  24. Martin Loos · 1 shared paper, 2021 · strength 0.11
  25. Yi Miao · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.